180 related articles for article (PubMed ID: 12953813)
1. L-asparaginase-based regimen in the treatment of refractory midline nasal/nasal-type T/NK-cell lymphoma.
Yong W; Zheng W; Zhang Y; Zhu J; Wei Y; Zhu D; Li J
Int J Hematol; 2003 Aug; 78(2):163-7. PubMed ID: 12953813
[TBL] [Abstract][Full Text] [Related]
2. Midline NK/T-cell lymphoma nasal-type: treatment outcome, the effect of L-asparaginase based regimen, and prognostic factors.
Yong W; Zheng W; Zhu J; Zhang Y; Wei Y; Wang X; Lin N; Xie Y; Xu B; Li J
Hematol Oncol; 2006 Mar; 24(1):28-32. PubMed ID: 16323259
[TBL] [Abstract][Full Text] [Related]
3. [Clinical characteristics and treatment of midline nasal and nasal type NK/T cell lymphoma].
Yong W; Zheng W; Zhang Y
Zhonghua Yi Xue Za Zhi; 2001 Jul; 81(13):773-5. PubMed ID: 11798962
[TBL] [Abstract][Full Text] [Related]
4. A prospective phase II study of L-asparaginase- CHOP plus radiation in newly diagnosed extranodal NK/T-cell lymphoma, nasal type.
Lin N; Song Y; Zheng W; Tu M; Xie Y; Wang X; Ping L; Ying Z; Zhang C; Deng L; Liu W; Zhu J
J Hematol Oncol; 2013 Jul; 6():44. PubMed ID: 23816178
[TBL] [Abstract][Full Text] [Related]
5. Study of L-Asparaginase, Vincristine, and Dexamethasone Combined With Intensity-modulated Radiation Therapy in Early-Stage Nasal NK/T-Cell Lymphoma.
Hu Y; Chen M; Song Y; Liu X; Gou F; Zhang J; Huang Y
Am J Clin Oncol; 2020 Apr; 43(4):257-262. PubMed ID: 31764026
[TBL] [Abstract][Full Text] [Related]
6. L-asparaginase-Based induction therapy for advanced extranodal NK/T-cell lymphoma.
Obama K; Tara M; Niina K
Int J Hematol; 2003 Oct; 78(3):248-50. PubMed ID: 14604284
[TBL] [Abstract][Full Text] [Related]
7. Comparative Study of L-Asparaginase-Based LOP Regimen Over CHOP Regimen Before Radiotherapy for Stage IIE Extranodal Nasal Type NK/T Cell Lymphoma: A Study of 2 Centers.
Huang L; Yuan B; Wu H; Chu H; Liu Y; Wu S; Li H; Lu H; Chen H
Clin Lymphoma Myeloma Leuk; 2017 Mar; 17(3):152-158. PubMed ID: 28215935
[TBL] [Abstract][Full Text] [Related]
8. [Prognostic analysis of patients with nasal-type NK/T-cell non-Hodgkin's lymphoma--a report of 93 cases].
Pan ZH; Huang HQ; Lin XB; Xia YF; Xia ZJ; Peng YL; Cai QQ; Lin TY; Jiang WQ; Guan ZZ
Ai Zheng; 2005 Dec; 24(12):1493-7. PubMed ID: 16351799
[TBL] [Abstract][Full Text] [Related]
9. L-asparaginase induced durable remission of relapsed nasal NK/T-cell lymphoma after autologous peripheral blood stem cell transplantation.
Nagafuji K; Fujisaki T; Arima F; Ohshima K
Int J Hematol; 2001 Dec; 74(4):447-50. PubMed ID: 11794702
[TBL] [Abstract][Full Text] [Related]
10. CHOP followed by involved field radiation: is it optimal for localized nasal natural killer/T-cell lymphoma?
Kim WS; Song SY; Ahn YC; Ko YH; Baek CH; Kim DY; Yoon SS; Lee HG; Kang WK; Lee HJ; Park CH; Park K
Ann Oncol; 2001 Mar; 12(3):349-52. PubMed ID: 11332147
[TBL] [Abstract][Full Text] [Related]
11. SVILE regimen, a combination of dexamethasone, vindesine, ifosfamide, pegaspargase, and etoposide, for treating relapsed/refractory extranodal natural killer/T-cell lymphoma, nasal type.
Wei L; Wang L; Cong J; Yang L; Ye J; Li X; Yao N; Yang J; Wang J
Leuk Res; 2020 Sep; 96():106422. PubMed ID: 32721642
[TBL] [Abstract][Full Text] [Related]
12. L-asparaginase in the treatment of refractory and relapsed extranodal NK/T-cell lymphoma, nasal type.
Yong W; Zheng W; Zhu J; Zhang Y; Wang X; Xie Y; Lin N; Xu B; Lu A; Li J
Ann Hematol; 2009 Jul; 88(7):647-52. PubMed ID: 19107482
[TBL] [Abstract][Full Text] [Related]
13. A five
Vittayawacharin P; Khuhapinant A
Hematology; 2021 Dec; 26(1):75-82. PubMed ID: 33427594
[TBL] [Abstract][Full Text] [Related]
14. The DDGP (cisplatin, dexamethasone, gemcitabine, and pegaspargase) regimen for treatment of extranodal natural killer (NK)/T-cell lymphoma, nasal type.
Zhang L; Li S; Jia S; Nan F; Li Z; Cao J; Fan S; Zhang C; Su L; Wang J; Xue H; Zhang M
Oncotarget; 2016 Sep; 7(36):58396-58404. PubMed ID: 27517317
[TBL] [Abstract][Full Text] [Related]
15. Immunophenotypic and clinical differences between the nasal and extranasal subtypes of upper aerodigestive tract natural killer/T-cell lymphoma.
Liu QF; Wang WH; Wang SL; Liu YP; Huang WT; Lu N; Zhou LQ; Ouyang H; Jin J; Li YX
Int J Radiat Oncol Biol Phys; 2014 Mar; 88(4):806-13. PubMed ID: 24495590
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and tolerance of pegaspargase-based chemotherapy in patients with nasal-type extranodal NK/T-cell lymphoma: a pilot study.
Wen JY; Li M; Li X; Chen J; Lin Q; Ma XK; Dong M; Wei L; Chen ZH; Wu XY
Asian Pac J Cancer Prev; 2014; 15(15):6275-81. PubMed ID: 25124611
[TBL] [Abstract][Full Text] [Related]
17. Combined chemoradiation for the management of nasal natural killer (NK)/T-cell lymphoma: elucidating the significance of systemic chemotherapy.
Guo Y; Lu JJ; Ma X; Wang B; Hong X; Li X; Li J
Oral Oncol; 2008 Jan; 44(1):23-30. PubMed ID: 17306611
[TBL] [Abstract][Full Text] [Related]
18. [Treatment option and outcome for patients with primary non-Hodgkin's lymphoma of the nasal cavity].
Yao B; Li YX; Song YW; Jin J; Liu YP; Wang WH; Wang SL; Sun YT; Yu ZH; Liu XF
Zhonghua Zhong Liu Za Zhi; 2006 Jan; 28(1):58-61. PubMed ID: 16737624
[TBL] [Abstract][Full Text] [Related]
19. Treatment of feline lymphoma using a 12-week, maintenance-free combination chemotherapy protocol in 26 cats.
Limmer S; Eberle N; Nerschbach V; Nolte I; Betz D
Vet Comp Oncol; 2016 Aug; 14 Suppl 1():21-31. PubMed ID: 24548273
[TBL] [Abstract][Full Text] [Related]
20. [Temporary effective treatment with L-asparaginase for a patient with refractory nasal NK/T-cell lymphoma].
Sakamoto E; Yamane T; Nakane T; Takeoka Y; Hirose A; Hagihara K; Nakamae H; Ohta K; Hirayama M; Ikura Y; Ohsawa M; Sawada T; Kitoh T; Hino M
Gan To Kagaku Ryoho; 2005 Nov; 32(12):1993-6. PubMed ID: 16282743
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]